|
Bcl-2 inhibitor | Combined therapy with other drugs | Targeted cancer type | No. of patients | Complete remission | Partial response | Stable disease | Phase | Researchers |
|
Oblimersen | Cisplatin and 5-fluorouracil | Advanced esophageal, gastroesophageal junction, and gastric carcinoma | 15 | 1 (metastatic gastric carcinoma with pulmonary metastases) | 2 (1 gastric carcinoma, 1 squamous cell carcinoma of the esophagus) | | I | Raab et al. [7] |
Gemcitabine | Refractory and advanced malignancies | 16 | 0 | 0 | 5 | I | Galatin et al. [8] |
Temozolomide and albumin-bound paclitaxel | Advanced melanoma | 32 | 2 | 11 | 11 | I | Ott et al. [9] |
|
Navitoclax (ABT-263) | None | SCLC or pulmonary carcinoid | 47 | 0 | 1 (SCLC) | 8 (5 SCLC, 3 atypical pulmonary carcinoid) | I | Gandhi et al. [10] |
None | Relapsed SCLC | 39 | 0 | 1 | 9 | II | Rudin et al. [11] |
None | Relapsed or refractory CLL | 29 | 0 | 9 | 7 | I | Roberts et al. [12] |
Irinotecan | Advanced solid tumors | 31 | 0 | 2 (1 Merkel cell carcinoma, 1 colon carcinoma) | 6 | I | Tolcher et al. [13] |
Erlotinib | Advanced solid tumors | 11 | 0 | 0 | 3 | I | Tolcher et al. [14] |
Rituximab | Relapsed or refractory CD20+ lymphoid malignancies | 29 | 6 (1 diffuse large B-cell lymphoma, 5 follicular lymphoma) | 10 (5 CLL/SLL, 4 follicular lymphoma, 1 lymphoma/Waldenström’s macroglobulinemia) | | I | Roberts et al. [15] |
Rituximab | Previously untreated B-cell CLL | 78 | 2 | 47 | 25 | II | Kipps et al. [16] |
|
Venetoclax (ABT-199) | Obinutuzumab | CLL and coexisting conditions | 216 | 107 | 76 | | III | Fischer et al. [17] |
Ibrutinib | CLL | 80 | 25 | 1 | | II | Jain et al. [18] |
Ibrutinib | CLL | 91 | 8 | 48 | 22 | II | Jones et al. [19] |
None | Relapsed or refractory non-Hodgkin lymphoma | 106 | 14 | 33 | 32 | I | Davids et al. [20] |
None | Acute myelogenous leukemia | 32 | 6 (2 CR, 4 CRi) | 0 | 6 | II | Konopleva et al. [21] |
Decitabine or azacitidine | Acute myeloid leukemia | 57 | 35 | 1 | 0 | I | DiNardo et al. [22] |
Bendamustine and obinutuzumab | CLL | 66 | 5 | 55 | | II | Cramer et al. [23] |
|
Obatoclax mesylate (GX15-070) | Bortezomib | Relapsed or refractory mantle cell lymphoma | 13 | 3 | 1 | 6 | I/II | Goy et al. [24] |
None | Myelodysplastic syndromes with anemia or thrombocytopenia | 24 | 0 | 0 | 17 | II | Arellano et al. [25] |
|
AT-101 | Paclitaxel and carboplatin | Several types of solid tumors (most common tumor type was prostate, N = 11) | 24 | 1 (esophageal cancer) | 4 (1 NSCLC, 3 prostate) | | I | Stein et al. [26] |
Docetaxel | Recurrent, locally advanced, or metastatic head and neck cancer | 22 | 0 | 3 | 12 | II | Swiecicki et al. [27] |
Cisplatin and etoposide | Extensive-stage SCLC | 27 | 0 | 10 | 11 | I | Schelman et al. [28] |
|